Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      COVID-19 Challenges Drive the Need for Resilient Supply Chains and Digital Healthcare in the Anti-Epileptic Drugs Market, Shaping the Post-Pandemic Landscape

      Research and Markets Logo

      News provided by

      Research and Markets

      Nov 06, 2023, 14:00 ET

      Share this article

      Share this article


      DUBLIN, Nov. 6, 2023 /PRNewswire/ -- The "Global Anti-Epileptic Drugs Market: Analysis By Drug Generation, By Distribution Channel, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2028" report has been added to  ResearchAndMarkets.com's offering.

      The global Anti-Epileptic Drugs (AEDs) market, valued at $9.39 billion in 2022, is poised to expand to $11.47 billion by 2028, with a steady Compound Annual Growth Rate (CAGR) of 3.39% during the forecast period from 2023 to 2028. This growth is attributed to the increasing effectiveness of AEDs in controlling seizures, accompanied by fewer side effects, resulting in improved patient compliance.

      Enhanced Treatment Landscape

      Anti-Epileptic Drugs (AEDs) have evolved significantly in recent years, becoming central in addressing various epilepsy-related syndromes and offering tailored care for patients. Beyond treating epileptic episodes, AEDs now play a pivotal role in personalized neurological treatment, contributing to the modern therapeutic approach. This transformation not only benefits patients but also fuels substantial growth in the healthcare industry, solidifying AEDs' importance.

      Market Segmentation Analysis

      • By Drug Generation: The global AEDs market is segmented into First Generation, Second Generation, and Third Generation. In 2022, Second Generation AEDs dominate the market due to their higher efficacy and reduced side effects compared to First Generation AEDs. Third Generation AEDs are expected to exhibit the fastest growth during the forecast period, driven by advanced pharmacological profiles, minimized adverse effects, and medical professionals' preference for newer treatments.
      • By Distribution Channel: The market is divided into three segments: drug stores & retail pharmacies, hospital pharmacies, and online providers. In 2022, drug stores & retail pharmacies hold the largest share, offering accessibility, immediate availability, and direct consultations with pharmacists. Online providers are expected to be the fastest-growing segment from 2023 to 2028, driven by convenience, digital healthcare advancements, and the ability to reach a wide geographic audience efficiently.
      • By Region: The global AEDs market is divided into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America leads the market, driven by its robust healthcare infrastructure, technological advancements, and innovative therapies. Asia Pacific is expected to grow at the fastest CAGR, particularly in India and China, due to rising epilepsy cases, healthcare developments, and pharmaceutical sector advancements.

      Global Anti-Epileptic Drugs (AEDs) Market Dynamics

      • Growth Drivers: The global Anti-Epileptic Drugs (AEDs) market's growth is fueled by the increasing prevalence of epilepsy and other Central Nervous System (CNS) diseases, enhanced awareness, and advanced therapeutic options. Factors such as the growing geriatric population, government initiatives, advancements in early diagnosis techniques, global expansion of pharmaceutical companies, and innovation in AED development contribute to market expansion.
      • Challenges: Patent expirations of key AEDs pose a challenge to the market's growth, requiring companies to innovate while addressing economic constraints. Other challenges include accessibility issues and associated adverse effects.
      • Market Trends: Emerging markets play a crucial role in AEDs market growth, investing in healthcare and offering growth potential and innovation. Trends such as advancements in Artificial Intelligence (AI) and Machine Learning (ML), increased research & development, integration of nasal sprays, drug delivery systems, genomic sequencing, and personalized medicine are expected to shape the market's future.

      Impact Analysis of COVID-19 and Way Forward:

      The global anti-epileptic drugs (AEDs) market encountered significant challenges in 2020 due to the COVID-19 pandemic. Key pharmaceutical regions, such as China and India, experienced supply chain disruptions leading to anti-epileptic drug shortages. These were further exacerbated by an unexpected surge in demand. The pandemic's focus also delayed routine epilepsy diagnoses and treatments.

      Concurrently, heightened pandemic-induced mental health issues interplayed with epilepsy care, emphasizing their intertwined relationship. Economic downturns highlighted concerns over drug affordability, especially where healthcare isn't universally available.

      Post-pandemic, the anti-epileptic drugs market landscape underscores the need for enhanced supply chain resilience and integrated digital healthcare. As the global community pivots to a new normal, opportunities emerge to reshape epilepsy care, prioritizing technological innovations, mental well-being, and fortified healthcare systems.

      Competitive Landscape and Recent Developments:

      The global Anti-Epileptic Drugs (AEDs) market is a fragmented space shaped by innovation and evolution. Multiple AED generations offer diverse treatments, exemplified by the shift from side-effect-prone first-generation drugs to third-generation ones with novel mechanisms of action. This diversity, with combined treatment approaches and unique drug effects, accentuates market fragmentation.

      Further, key players in the Anti-Epileptic Drugs (AEDs) market are:

      • Pfizer Inc.
      • UCB Inc.
      • Novartis AG
      • GlaxoSmithKline Plc
      • Sanofi S.A.
      • Eisai Co. Ltd.
      • Johnson & Johnson (Janssen Pharmaceuticals)
      • Takeda Pharmaceutical Company Limited
      • Sumitomo Pharma Co., Ltd. (Sunovion Pharmaceuticals)
      • Abbott Laboratories
      • TEVA Pharmaceutical Industries Limited
      • Viatris Inc. (Mylan)
      • Merck & Co., Inc.
      • SK Biopharmaceuticals Co., Ltd.

      Product-wise, Pfizer showcases a plethora of Anti-Epileptic Drugs, ensuring varied potency, sustainability, and therapeutic potential, including the innovative compound Lyrica for neuropathic pain. Novartis, in its repertoire, boasts a blend of broad-spectrum and targeted AEDs, with the likes of Tegretol and Trileptal. Strategic collaborations, like UCB's partnership with Microsoft for seizure prediction wearables, and M&As, like UCB's acquisition of Zogenix, influence the market landscape. New offerings, like Sun Pharmaceutical's Brivaracetam and Marinus Pharmaceuticals' ZTALMY, continue reshaping the market dominated by major brands.

      Key Topics Covered:

      1. Executive Summary

      2. Introduction

      3. Global Market Analysis

      4. Regional Market Analysis

      5. Impact of COVID-19

      6. Market Dynamics
      6.1 Growth Driver
      6.1.1 Growth in Central Nervous System (CNS) Diseases
      6.1.2 Growing Geriatric Population
      6.1.3 Increasing Prevalence of Epilepsy
      6.1.4 Government Initiatives and Funding
      6.1.5 Enhanced Awareness and Advancements in Early Diagnosis Techniques
      6.1.6 Global Expansion Of Pharmaceutical Companies
      6.1.7 Involvement of Public-Private Partnerships
      6.1.8 Advancement in Antiepileptic Drugs Development
      6.2 Challenges
      6.2.1 Patent Expirations
      6.2.2 Lack of Accessibility and Associated Adverse Effects
      6.3 Market Trends
      6.3.1 Advancements in Artificial Intelligence (AI) and Machine Learning (ML)
      6.3.2 Increasing Research & Development
      6.3.3 Emerging Markets
      6.3.4 Integration of Nasal Sprays as Rescue Therapy
      6.3.5 Development of Drug Delivery Systems
      6.3.6 Integration of Genomic Sequencing and Personalized Medicine

      7. Competitive Landscape

      8. Company Profiles

      For more information about this report visit https://www.researchandmarkets.com/r/7qanea

      About ResearchAndMarkets.com
      ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

      Media Contact:

      Research and Markets
      Laura Wood, Senior Manager
      [email protected]    

      For E.S.T Office Hours Call +1-917-300-0470 
      For U.S./CAN Toll Free Call +1-800-526-8630
      For GMT Office Hours Call +353-1-416-8900

      U.S. Fax: 646-607-1904
      Fax (outside U.S.): +353-1-481-1716 

      Logo:  https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg 



      SOURCE Research and Markets

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.